ppeptidewhy
Side by side

Compare peptides.

See why people discuss them, what the evidence supports, and where amount information comes from.

Choose two compounds

Add up to four if you need to. Evidence labels apply to specific claims and products.

Compare more (up to four)

Metabolic & appetite

Retatrutide

Retatrutide acts on GIP, GLP-1, and glucagon receptors. It is an investigational compound in human trials for weight and metabolic outcomes.

Why people are interested

Retatrutide draws attention because human trials are studying its effects on body weight, blood sugar, and liver fat through three hormone-receptor pathways.

What the research supports

Phase 2 trials reported promising results in selected participants. Retatrutide remains investigational; a clinical trial result does not approve or verify a seller's research vial.

Clinical or label amounts

Human trial groups

1, 4, 8, or 12 mg

Once weekly in the phase 2 obesity trial

Specific to the named study or medicine, not this research vial.

Retatrutide phase 2 trial (NEJM, 2023) ↗

Publicly reported amounts

Amount in one post: started at 1 mg; later tried 2 mg, then returned to 1 mg

One checked post, not a typical amount or a recommendation.

Public reports and source limits →
Read the full Retatrutide profile and sources →
Metabolic & appetite

Tirzepatide

Tirzepatide acts on GIP and GLP-1 receptors. It has been studied in human medicine products for blood sugar and metabolic effects.

Why people are interested

Tirzepatide is well known because prescription versions are used for type 2 diabetes, chronic weight management, and certain sleep-apnea patients. JD-2TR is a seller code associated with tirzepatide in listed batch reports.

What the research supports

The strongest evidence belongs to manufactured prescription tirzepatide products studied in clinical trials. FDA approval applies to those products and specific indications, not automatically to a research-only JD-2TR vial.

Clinical or label amounts

Prescription product label

2.5–15 mg

Once weekly in adults

Specific to the named study or medicine, not this research vial.

Mounjaro prescribing information (2026) ↗

Publicly reported amounts

Amount in one post: 2.5 mg each time from a stated 10 mg dry vial

One checked post, not a typical amount or a recommendation.

Public reports and source limits →
Read the full Tirzepatide profile and sources →

FDA-approved uses belong to named prescription products and indications; they do not transfer to an online research vial. Human, animal, cell, and anecdotal evidence are different. How we check sources →